Loading clinical trials...
Loading clinical trials...
Multicenter, Open-label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen for 13 Cycles in 1650 Healthy Female Subjects
The aim of the present study is to prove efficacy and safety of a new contraceptive patch.
Age
18 - 35 years
Sex
FEMALE
Healthy Volunteers
No
Lanús Oeste, Buenos Aires, Argentina
San Isidro, Buenos Aires, Argentina
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Rosario, Santa Fe Province, Argentina
Ashfield, New South Wales, Australia
Adelaide, South Australia, Australia
North Adelaide, South Australia, Australia
Clayton, Victoria, Australia
Start Date
April 1, 2009
Primary Completion Date
September 1, 2011
Completion Date
September 1, 2011
Last Updated
December 5, 2014
1,694
ACTUAL participants
Ethinylestradiol/Gestodene (BAY86-5016)
DRUG
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06672016